dc.contributor.author | World Health Assembly, 15 | |
dc.coverage.spatial | Geneva | EN |
dc.date.accessioned | 2014-10-05T17:08:07Z | |
dc.date.available | 2014-10-05T17:08:07Z | |
dc.date.issued | 1962 | |
dc.identifier.govdoc | A15/P&B/WP/22 | |
dc.identifier.govdoc | A15/P&B/WP/22 Rev.1 | |
dc.identifier.uri | https://iris.who.int/handle/10665/135892 | |
dc.description | (Agenda item 2.2.3) | EN |
dc.language.iso | en | EN |
dc.publisher | World Health Organization | EN |
dc.subject | Pharmaceutical products | EN |
dc.subject.mesh | Pharmaceutical Preparations | EN |
dc.subject.mesh | Drug Evaluation | EN |
dc.subject.mesh | Substance-Related Disorders | EN |
dc.title | Needs of basic requirements for clinical evaluation of drugs and international exchange of information on their value and safety: amendment proposed by the Delegation of Austria to the resolution contained in Document A15/P&B/WP/17 | EN |
dc.type | Governing body documents | EN |